{'fraction_non_alphanumeric': 0.01948051948051948, 'fraction_numerical': 0.0, 'mean_word_length': 5.425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
IN VITRO REPROGRAMMING OF MURINE GALL BLADDER CELLS TOWARDS THE BETA CELL FATE

Diabetes mellitus type I is characterized by the loss of insulin‐secreting β‐cells in pancreatic islets. One suitable cell therapy approach would involve an autologous source of cells that could be expanded and reprogrammed in vitro to β‐cells, which could then be transplanted back to the patient without the need of long‐term immune suppression. We hypothesized that gall bladder cells (GBCs) could fulfill these requirements, as removal of the human gall bladder is a minimally invasive surgery. Additionally, the extrahepatobiliary system and ventral pancreas share a common development origin, and therefore we reasoned that these cells would be more readily reprogrammable to β‐cells.